United States · 
Who invested in NovaDigm Therapeutics?
NovaDigm Therapeutics's investors include Domain Associates and RMI LLC.
2014
$21MSeed$14MSeries B
United States · Series B startup
Who invested in NovaDigm Therapeutics
Funding summaryUpdated 26 Oct 2026
$35Mraised across 2 rounds since 2013, from 2 sources
$21MSeed$14MSeries B
- Latest round
- Series B, $14MOct 2013
- Biggest round
- $21MSeed · Feb 2013
- Investors
- 2
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Seed, $21M Feb 2013
- Biggest round
- $21M Seed · Feb 2013
- Between rounds
- 7 months from the last two
The rounds
- Oct 2013Series B$14M2 new
Reported by finsmes.comSEC filing: $7.0M sold, first sale Sept 2013
- Feb 2013Seed$21M
No investor was named in the report.
Reported by sec.govSEC filing: $21M sold, first sale Jun 2008
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about NovaDigm Therapeutics
How much has NovaDigm Therapeutics raised?
NovaDigm Therapeutics has raised $35M across 2 rounds since 2013.
When did NovaDigm Therapeutics last raise?
NovaDigm Therapeutics's most recent round was a Series B of $14M in Oct 2013.
What was NovaDigm Therapeutics's biggest round?
NovaDigm Therapeutics's largest round on record is $21M (Seed), in Feb 2013.
Who backed NovaDigm Therapeutics first?
NovaDigm Therapeutics's first round on record, in Oct 2013, was backed by Domain Associates and RMI LLC.
What stage is NovaDigm Therapeutics at?
NovaDigm Therapeutics's latest named round is a Series B, in Oct 2013.
Where is NovaDigm Therapeutics based?
NovaDigm Therapeutics is based in the United States.
Companies like NovaDigm Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.